| Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review N Kerckhove, A Collin, S Condé, C Chaleteix, D Pezet, D Balayssac Frontiers in pharmacology 8, 86, 2017 | 349 | 2017 |
| State-dependent properties of a new T-type calcium channel blocker enhance CaV3. 2 selectivity and support analgesic effects A Francois, N Kerckhove, M Meleine, A Alloui, C Barrere, A Gelot, ... Pain 154 (2), 283-293, 2013 | 127 | 2013 |
| Cav3. 2 calcium channels: The key protagonist in the supraspinal effect of paracetamol N Kerckhove, C Mallet, A François, M Boudes, J Chemin, T Voets, ... PAIN® 155 (4), 764-772, 2014 | 78 | 2014 |
| Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin L Poupon, S Lamoine, V Pereira, DA Barriere, S Lolignier, F Giraudet, ... Neuropharmacology 140, 43-61, 2018 | 72 | 2018 |
| Long-term prevalence of sensory chemotherapy-induced peripheral neuropathy for 5 years after adjuvant FOLFOX chemotherapy to treat colorectal cancer: a multicenter cross … M Selvy, B Pereira, N Kerckhove, C Gonneau, G Feydel, C Pétorin, ... Journal of clinical medicine 9 (8), 2400, 2020 | 61 | 2020 |
| Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: a single center cross-sectional study M Selvy, N Kerckhove, B Pereira, F Barreau, D Nguyen, J Busserolles, ... Frontiers in Pharmacology 12, 637593, 2021 | 40 | 2021 |
| Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives L Poupon, N Kerckhove, J Vein, S Lamoine, N Authier, J Busserolles, ... Expert opinion on drug safety 14 (8), 1269-1282, 2015 | 39 | 2015 |
| New SPE-LC-MS/MS method for the simultaneous determination in urine of 22 metabolites of DEHP and alternative plasticizers from PVC medical devices J Pinguet, N Kerckhove, T Eljezi, C Lambert, E Moreau, L Bernard, ... Talanta 198, 377-389, 2019 | 38 | 2019 |
| Replacement of current opioid drugs focusing on MOR-related strategies J Busserolles, S Lolignier, N Kerckhove, C Bertin, N Authier, A Eschalier Pharmacology & Therapeutics 210, 107519, 2020 | 27 | 2020 |
| Efficacy and safety of a T‐type calcium channel blocker in patients with neuropathic pain: A proof‐of‐concept, randomized, double‐blind and controlled trial N Kerckhove, B Pereira, S Soriot‐Thomas, H Alchaar, R Deleens, ... European Journal of Pain 22 (7), 1321-1330, 2018 | 25 | 2018 |
| Ethosuximide improves chronic pain-induced anxiety-and depression-like behaviors N Kerckhove, L Boudieu, G Ourties, J Bourdier, L Daulhac, A Eschalier, ... European Neuropsychopharmacology 29 (12), 1419-1432, 2019 | 23 | 2019 |
| Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists’ professional practices M Selvy, B Pereira, N Kerckhove, J Busserolles, F Farsi, V Guastella, ... Supportive Care in Cancer 29, 4033-4043, 2021 | 22 | 2021 |
| Systematic review and meta-analysis of the prevalence of chronic pain among patients with opioid use disorder and receiving opioid substitution therapy J Delorme, N Kerckhove, N Authier, B Pereira, C Bertin, C Chenaf The Journal of Pain 24 (2), 192-203, 2023 | 19 | 2023 |
| Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind … N Kerckhove, J Busserolles, T Stanbury, B Pereira, V Plence, F Bonnetain, ... Bmj Open 9 (6), e027770, 2019 | 17 | 2019 |
| Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology N Kerckhove, A Collin, S Conde, C Chaleteix, D Pezet, D Balayssac, ... Bulletin du Cancer 105 (11), 1020-1032, 2018 | 17 | 2018 |
| Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome–IBSET: protocol of a randomised, parallel … N Kerckhove, J Scanzi, B Pereira, D Ardid, M Dapoigny BMJ open 7 (7), e015380, 2017 | 17 | 2017 |
| Clinical assessment of new antineuropathic strategies for chemotherapy-induced peripheral neuropathy: pain should not be the principal endpoint N Kerckhove, B Pereira, D Pezet, D Balayssac Pain 158 (1), 180-182, 2017 | 15 | 2017 |
| The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized … M Selvy, M Cuménal, N Kerckhove, C Courteix, J Busserolles, ... Expert opinion on drug safety 19 (6), 707-733, 2020 | 14 | 2020 |
| eDOL mHealth app and web platform for self-monitoring and medical follow-up of patients with chronic pain: observational feasibility study N Kerckhove, N Delage, S Cambier, N Cantagrel, E Serra, F Marcaillou, ... JMIR Formative Research 6 (3), e30052, 2022 | 13 | 2022 |
| Neuropathies périphériques chimio-induites: symptomatologie et épidémiologie N Kerckhove, A Collin, S Condé, C Chaleteix, D Pezet, D Balayssac, ... Bulletin du Cancer 105 (11), 1020-1032, 2018 | 11 | 2018 |
